Cocrystal Pharma adopts 2025 Equity Incentive Plan with 1.5M initial shares

Cocrystal Pharma, Inc.

Plan effective March 31, 2025; shareholder approval required under Nasdaq rules.
Initially authorizes 1,500,000 shares of common stock for awards.
Annual increase on Jan 1 each year: 5% of outstanding shares, up to 2,500,000 per year (total cap 4,000,000).
Plan expires March 31, 2035; awards can include options, SARs, restricted stock, RSUs, performance shares/units, cash.
No specific officer/director grants announced; plan is broad-based for employees, consultants, directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.